A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia [Abstract]

Bayer, Antony James ORCID: https://orcid.org/0000-0002-7514-248X, Pratt, R. D. and Kumar, D. 2004. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia [Abstract]. European Journal of Neurology 11 (S2) , pp. 36-37. 10.1111/j.1468-1331.2004.00919.x

Full text not available from this repository.

Abstract

Background: Patients with vascular dementia (VaD) benefit from treatment with donepezil. Objective: To compare the cognitive effects of donepezil versus placebo, in patients with evidence on imaging suggestive of cortical or subcortical VaD. Methods: A subanalysis of data from two randomized, double-blind, placebo-controlled, 24-week, parallel-group studies in patients with probable or possible VaD. Patients received placebo or donepezil (5 or 10 mg/day). Results: A total of 1219 VaD patients were enrolled: 131 (11%) had predominant cortical lesions (cortical VaD); 625 (51%) had predominant subcortical lesions and white matter disease without cortical lesions (subcortical VaD). 90% of cortical patients had abrupt onset, while 57% of subcortical patients had slowly progressive symptoms. Donepezil treatment was associated with significant benefits in cognition versus placebo in patients with both cortical and subcortical VaD. In patients with cortical VaD, the ADAS-cog least squares (LS) mean change from baseline scores at week 24 LOCF were: 0.204 in the placebo group, –2.29 in the donepezil 5 mg/day group (P < 0.05 versus placebo), and –2.57 in the donepezil 10 mg/day group (P < 0.05 versus placebo). In patients with subcortical VaD, the corresponding ADAS-cog scores were: placebo group 0.128, donepezil 5 mg/day – 1.05 (P < 0.05 vs. placebo), and donepezil 10 mg/day )1.12 (P < 0.05 vs. placebo). Conclusions: Donepezil significantly improved cognition in patients with VaD, with cortical or with subcortical vascular lesions. Placebo-treated patients with cortical or subcortical VaD did not show a decline in cognition over 24 weeks. These results indicate that donepezil is an effective treatment for the cognitive symptoms of both cortical and subcortical VaD.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Additional Information:	Abstracts of the 8th Congress of the EFNS, Paris, 2004 - Poster session 1
Publisher:	Wiley
ISSN:	1351-5101
Last Modified:	24 Oct 2022 11:23
URI:	https://orca.cardiff.ac.uk/id/eprint/47939

Actions (repository staff only)

Edit Item